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Significance of Pathophysiology
The Pathophysiology of Melanoma
Dianna Lauer RN, BSN
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A	50 year old	Caucasian	female,	with	blonde	hair	and	fair	skin	presented	to	the	office	for	a	routine	physical	exam.	The	patient	has	a	family	history	of	melanoma	and	has	been	visiting	the	office	every	six	months	due	to	recurring	basal	cell	lesions.	A	nevi	on	the	right	dorsal	forearm	has	been	under	watch	for	a	year	now,	with	no	change	or	issue.	The	practitioner	suggest	to	remove	the	nevi	for	biopsy	due	to	the	risk	factors	the	patient	has.	A punch biopsy is done on the nevi	and	the	pathology	report	confirms	melanoma	stage		II.	A	wide	excision	of	the	right	forearm	with sentinel lymph	node	biopsy	is	done.	The	pathology	report	for	the	sentinel	lymph	biopsy	comes	back	negative	for	metastasis.	The	patient continues to follow up with the practitioner	every	three	to	six	months.	Four years down the road the patient discovers	a	lump	under	the	right	axilla.	The	patient	is	sent	to	a	surgeons	office	for	a	fine needle aspiration to confirm pathology.The pathology	report	confirms	malignancy.	A	biopsy	reports	recurrent	metastatic	melanoma	stage	IIIB.	A	PET	scan	is	ordered	and	confirms	malignancy	contained	to	the	right	axilla	region.	The patient is scheduled	for	dissection	of	the	right	axillary	lymph	nodes.	Approximately	eighteen	lymph	nodes	were	removed,	with	three	positive	lymph	nodes	showing	melanoma.	The	patient	is	then	recommended	for	adjuvant	therapy.	*	Real	patient	experience,	posted	with	permission*
Using	the	ABCDE	method,	practitioners	must	know	what	they	are	looking	for,	any	suspicion	of	melanoma,	or	skin	cancer	must	be	taken	cautiously	and	a	biopsy	should	be	done.	Knowing	the	patient	physical	and	social	history	will	help	make	the	decision	easy.	Practitioners	must	be	aware	of	age	if	there	is	suspicion	because	“increasing	age	leads	to	worse	survival	rates	in	stages	I,	II,	and	III”	(Ribero et	al,	p.	624,	2018).	Health care providers must hasknowledge of the pathyophysiology andetiology of melanoma in order todistinguish the signs and symptoms	and	diagnose	and	treat	the	condition.	
There	are	many	types	of	skin	cancer	prevalent	in	the	world	today.	The	three	most	common	types	of	skin	cancer	are	basal	cell	carcinoma,	squamous	cell	carcinoma,	and	melanoma	(Watson	et	al,	2015).	This poster presentation willfocus on the skin cancer	known	as	melanoma.	In	the	words	of	Hawryluk &	Tsao	(2014),	“Melanoma	is	an	aggressive	malignancy	borne	of	melanocytes,	the	pigment-generating	cells	of	the	skin”.	In	2013,	malignant	melanoma	had	an	estimated	76,	690	new	cases	in	the	United	States,	with	9,480	deaths,	that	accounts	for	sixty	percent	of	deaths	from	skin	cancers	(Hawryluk &	Tsao,	2014).	Melanoma	has	shown	an	“increase	of	3-6%	over	the	last	few	decades,	making	this	one	of	the	fastest	growing	cancers	worldwide”	(Liu	et	al,	p.	1,	2014).	Melanoma	is	now	a	common	occurrence	in	everyday	practice.	Nurse	practitioners	and	physicians	need	to	be	aware	of	risk	factors,	keep	watch	on	nevi,	and	consult	the	correct	dermatological	physicians	if	there	is	worry	of	melanoma.	Within	this	poster	presentation	we	will	dive	into	the	pathophysiology	of	melanoma	including	a	patient	scenario,	with	risk	factors,	sign	and	symptoms,	and	implications	of	nursing	care.	
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Clinical Manifestations & Staging
Melanoma	is	a	very	treatable	cancer	if	diagnosis	and	treatment	are	in	the earlystages.	In	2014	an	estimate	of	“	nearly	76,	100	new	cases	of	melanoma	of	the	skin	will	be	diagnosed	and	about	9,710	people	will	die	due	to	the	disease	within	the	year	alone”	(Liu	et	al,	p.	1,	2014).	This	makes	melanoma	one	of	the	fastest	growing	cancers	in	the	United	States.	The pathophysiology can be technical	when	diagnosis	of	malignant	melanoma	and	treatment	options	all	depend	on	age	and	the	stage	of	the	cancer.	Treatment	has	become	more	sophisticated,	but	diagnosis	and	early	detection	have	also	become	very specific.	Discovering	the	specific	markers	and	mutations	of	melanoma	can	allow	for	early	detection	and	eliminate	the	amount	of	cytotoxic	treatment	a	patient	must	receive	(Liu	et	al,	2014).	The practitioner	must	force	efforts	for	education	and	awareness	of	the	disease	and	make	it	communitywide.	The	cost	for	treating	melanoma	has	increased	significantly,	specifically	about	250%	(Watson	et	al,	2015).	Early	detection	and	treatment	will	decrease	morbidity	and	mortality	rate	as	well	as	decrease	unnecessary	treatment.	
Conclusion
• Routine	annual	physical	exams
• Nevus	count
• Monitoring suspicious nevi
• In	depth	familial	history
• Routine	lab workup
• Punch	biopsy	of	any	suspicious	nevi
• Consult	to specialists
• Use	of	microscope/dermascopewhen evaluating skin
• Use	of	MEDS- and automatedmelanoma diagnosis system
• Blood	assay	for	those	termed	cancer	free	to	predict	recurrence	of	melanoma	
• (MITF)- microphthalmia	transcription	factor- used	to	detect	melanoma
• History	of sunburns with blistering
• Education	on	reducing	UV	exposure/	wearing	sunscreen	and	clothing	that	covers	most	of	the	skin/eyes.
• Education	on tanning	bed	exposure
• Education	on smoking cessation
• Emotional support	to	those	diagnosed	with	metastatic	melanoma
• Education	on best treatmentoptions	and	patients	age
• Expediting	care if patient doescome back	positive	for	metastatic	melanoma with biopsy of possible	metastasis
• Educating	on	all	signs/symptoms	and	risk	factors
Implications of 
Nursing Care
Underlying Pathophysiology
Melanocytes	can	be	found	on	the	epidermis	of	the	skin.	Melanocytes	are	responsible	for	producing	the	pigment	melanin,	which	gives the skin its color. Cutaneous melanomais caused	by malignant	neoplasms	of	the	melanoctyes (Liu et al, 2014).The etiology and pathogenesis	of	melanoma	can	be	explained	by	Ultraviolet(UV)	radiation,	melanocytic	nevi,	and	molecular	changes	associated	with	malignantmelanoma.	It	is	known	that	“one	or	more	blistering	sunburn	during	childhood	or	adolescence	more	than	doubles	the	risk	for	melanoma	later	in	life”	(Liu	et	al,	p.	3,	2014).	UV	radiation	can	make	DNA	mutations	occur,	forming	pyrimidine	dimers	or	deamination	of	cystosine into	thymidine	(Liu	et	al,	2014).Another etiology are melanocytic nevi. Nevi,	or	moles,	are	completely benign lesionsconcentrated with a large amount of melanocytes	which	give	them	a	darker	pigmentation	on	the	skin.	When	nevi	begin	to	change	in	shape,	color,	or	texture	we	begin	to	worry	that	malignant	melanoma may be present	(Liu	et	al,	2014).	Catching	thenevi in this early phase results in an extremely	high	survival	rate.		Practitioners	should	use	the	ABCDE’s	of	melanoma.	This	looks	at	(A)	asymmetry,	(B)	border,	(C)	color,	(D)	diameter,	and	(E)	evolving	(American	Academy	of	Dermatology,	2018).If	melanoma	is	not	caught	before	it	metastasizes	into	cutaneous	or	subcutaneous	tissue	the	result	is	a	malignancy.	In	order	to	treat	malignant	melanoma	specific	molecular	changes	must	be	identified	in	order	to	use	the	best	treatment	therapies.	There	are	eight	different	mutations	that	may	occur	due	to	genetic	susceptibility.	The	mutations	include	BRAF,	NRAS,	P13K-ATK/PTEN,	p53,	CD4K/CDKN2A,	c-KIT,	MC1R,	and	cadherin	(Liu	et	al	2014).	Tumor progression:1. Benign	melanocytic	nevi2. Atypical/dysplastic nevi	3. Radial	growth4. Vertical	growth5. Metastasis
Early	recognition	and	treatment	of	melanoma is crucial.	When	caught	in	the	early	stages	melanoma is easily treatable.	When mutations occur is when things gettricky for the practitioner.UV	exposure	and	age	are	the	biggest	contributors	to	melanoma	(	Watson	et	al,	2015).	With	practitioners	knowing	this,	they	must	take	time	to	evaluate	the	entirety	of	the skin,	watch	for	any	change,	as	well	as	be	responsible	for	educating	the	patient	on	risk	factors	and	signs	and	symptoms	of	melanoma	(Chang	et	al,	2014).	
• Change	in existing mole
• New	spot	or	patch on the skin
• A	spot	that	looks	like	changing	freckle/age spot
• Dark	streak	under	fingernail/toenail
• Band	of darker skin around finger/toenail
• Slowly	growing	patch	of	thick	skin	that	looks	like	a	scar(American	Academy	of	Dermatology,	2018)
Stage Description
0 confined to the epidermis (also known as melanoma in situ)
I No more than 2 mm thick and may or may not be ulcerated. Has not spread to nearby lymph nodes or to distant sites
II atleast 1.01 mm and may be thicker than 4.0 mm. May or may not be ulcerated. Has not spread to nearby lymph nodes 
or to distant sites
IIIA no more than 2.0 mm thick. May or may not be ulcerated. Has spread to 3 or less lymph node(s) but is so small It can 
only be seen under a microscope. Has not spread to distant sites
IIIB no sign of the primary cancer AND- Has spread to only one lymph node –OR- has spread to small areas of nearby skin 
but has not spread to distant sites. OR the cancer is no more than 4.0 mm thick. May or may not be ulcerated -AND- has 
spread to only one lymph node -OR- has spread to very small areas of nearby skin -OR- has spread to two or three lymph 
nodes but has not spread to distant sites.
IIIC no sign of primary cancer AND- has spread to one or more lymph node -OR- has spread to very small areas of nearby 
skin -OR- has spread to any lymph nodes that are clumped together. Has not spread to distant sites. OR no more than 
4.0 mm thick. May or may not be ulcerated AND- has spread to one or more lymph nodes -OR- has spread to very small 
areas of nearby skin -OR- has spread to lymph nodes that are clumped together. It has not spread to distant sites OR is 
between 2.1 and 4.0 mm OR thicker than 4.0 mm. May or may not be ulcerated AND- spread to one or more lymph 
nodes -OR- spread to very small areas of nearby skin -OR- has spread to lymph nodes that are clumped together. Has 
not spread to distant sites. OR is thicker than 4.0 mm and is ulcerated AND- has spread to no more than 3 lymph nodes -
OR- has spread to very small areas of nearby skin. Has not spread to distant sites
IIID Thicker than 4.0 mm and is ulcerated AND- has spread to very small areas of nearby skin -OR- has spread to lymph 
nodes that are clumped together. Has not spread to distant sites. 
IV Any thickness and may or may not be ulcerated. May or may not have spread to nearby lymph nodes. Has spread to 
distant lymph nodes or organs such as the lungs, liver, or brain.
Signs and Symptoms
(American	Cancer	Society,	2019).
Melanoma can develop in an existing mole or look like a new mole 
(American Academy of Dermatology 2018)
(McMaster	Pathophysiology	Review,	2018)Staging	involves	the	size,	degree	of	local	invasion,	and	the	extent	of	where	it	has	spread(McCance et al, p. 1204, 2018).
